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journal homepage: http://ees.elsevier.com/epagEvaluation of persistent pulmonary hypertension
of the newborn (PPHN) in Upper EgyptqPersistent Pulmonary hypertension of the newborn (PPHN)
occurs in 1.9 per 1000 live births, but a wide variation in the
incidence (0.43–6.82 per 1000 live births) has been reported be-
tween centers.
Persistent pulmonary hypertension of the newborn is a
complex disorder that is associated with a wide array of car-
diopulmonary diseases and is characterized by marked pul-
monary hypertension and altered vasoreactivity, leading to
the right-to-left shunting of blood across the patent ductus
arteriosus and/or foramen ovale.
PPHN is apotentially fatal complicationof the circulatorymal-
adaptation. It leads to profound hypoxemia secondary to right-to-
left shunting across the foramenovale and/orductus arteriosus as a
result of increased pulmonary venous return (PVR).
Treatment of PPHN aims at maximizing pulmonary blood
ﬂow and minimizing PVR without compromising cardiac out-
put. A range of therapeutic options are available for the man-
agement of PPHN including: extracorporeal membrane
oxygenation (ECMO), high frequency ventilation (HFV), sur-
factant and inhaled nitric oxide (iNO). The high cost of these
technically demanding modalities is the main concern for
developing countries. Inability to provide and maintain the re-
quired training and expertise is also an issue.
1. Aim of the study
To Assess The Magnitude of The Problem, Risk Factors,
Clinical Proﬁle, Some Available Therapeutic Modalities and
Outcome of PPH.Peer review under responsibility of Egyptian Pediatric Association
Gazette.
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2.1. Design:
A random, cross sectional observational, prospective study.
Period: from 1st June 2008 to the end of June 2010.
Place of study: Neonatal intensive Care Units (NICU) at
Sohag & Assiut University Hospitals.
Patients: 54 Newborns.2.2. Inclusion criteria:
1) >37 weeks’ gestation,
2) Absence of structural congenital heart diseases,
3) Admitted to the NICU between June 1, 2008 and 30
June 2010.2.3. Exclusion criteria:
1) Cardiac arrest or terminal disease (arterial pH <6.80,
bradycardia <90 beats/minute or unrecordable blood
pressure),
2) Preterm babies,
3) CNS cause of cyanosis.
2.4. Diagnosis of PPHN is based on:
Tachypnea, tachycardia, respiratory distress, central cyanosis,
heart murmur or abnormal heart sounds, echocardiography
and blood gas differences.
2.5. Right-to-left shunting is evidenced by:
A discrepancy in the pre- and post-ductal saturations; a Pa02
difference of at least 20 between the pre (right radial) and post
(umbilical) ductal arterial blood sample.
Or pulse oximetry ﬁndings of preductal (right ﬁnger) oxy-
gen saturation (Sa02) exceed post-ductal (toe) Sa02 by 5%.
Echocardiography demonstrates the absence of congenital
heart diseases and presence of right to left shunts through pat-
ent foramen ovale and for patent ductus arteriosus.he Egyptian Pediatric Association.
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– Full antenatal and postnatal histories,
– Full clinical examination,
– Serum glucose, calcium, hematocrit, WBC with differential,
platelet count, serum electrolytes, lumbar puncture and
blood cultures (if suspected septicemia),
– Pulse oximetry: for transcutaneous oxygen estimations of
preductal (right ﬁnger), postductal (right toe),
– Serial arterial blood gases,
– Chest X-ray,
– Cranial ultrasound of the head (in some selected brain
insult),
– Electrocardiogram,
– Echocardiogram,
– Continuous monitoring of oxygenation, blood pressure,
and perfusion.Table 1. Demographic data of studied neonates.
Variable No. %
Gestational age (weeks)
Full term 42 77.8
Post-term 12 22.2
Birth weight (kg)
Appropriate for date 34 62.9
Large for date 12 22.2
Small for date 8 14.8
Gender
Boys 31 57.4
Girls 23 42.6
Mode of delivery
Vaginal 19 35.2
LSCS 27 50.0
USCS 8 14.8
Age of presentations
At birth 6 11.1
2–3 days after birth 24 44.4
3–5 days after birth 16 29.7
>5 days after birth 8 14.8
Hospital delivery 42 77.8
Home delivery 12 22.22.7. Medications & protocols for administration:
– Pancuronium (pavulon):if baby needs mechanical venti-
lations: In a dose of 0.05–0.15 mg/kg/dose IV bolus q1–
2 h, alternatively, 0.01–0.1 mg/kg/h IV continuous
infusion.
– Dopamine: if baby hypotenuse (shocked): continuous
infusion:2–20 mcg/kg/min IV.
– Dobutamine (Dobutrex): if baby hypotenuse (shocke-
d):In 2–20 mcg/kg/min IV Sodium bicarbonate: Slow
bolus infusion: 2–3 mEq/kg IV for neonates with acido-
sis and guided by improvement of arterial blood gases.
– Sodium bicarbonate: Slow bolus infusion: 2–3 mEq/kg
IV for neonates with acidosis and guided by improve-
ment of arterial blood gases.
– Oral Sildenaﬁl citrate: given as follows:
 The solution for sildenaﬁl was prepared by crushing a
50 mg tablet of sildenaﬁl in Orabase (diluents) to make
a concentration of 2 mg/ml.
 The protocol for dosing was
 ﬁrst dose of 1 mg/kg (0.5 ml/kg) within 30 min after a-
dmission to NICU,
 Dosing every 6 h,
 Dose could be doubled (1 ml/kg) if the oxygenation did
not improve and blood pressure remained unstable, and
 The treatment was discontinued if there was no signiﬁ-
cant change in oxygenation after 36 h, or patient has r-
eceived eight doses. This strategy had been subjected to
many previous controlled trial evaluations.
– Magnesium sulfate:
 A loading dose of 250 mg/kg of magnesium sulfate IV
over 10–15 min.
 If a clinical response is obtained once the serum magne-
sium level exceeds 3,5 mmollL given between 20 and 7-
5 mg/kg for 2–5 days, while maintaining a blood level of
between 3–5 and 5,5 mmol/L.10–122.8. Mechanical ventilation:
Used in neonates with
1. Extreme acidosis (pH<7.1 0),
2. Resistance to treatment,
3. Severe neonatal pneumonia,
4. Massive lung collapse, and
5. Severe parenchymal lung diseases.
2.9. Follow up:
For the ﬁrst six months, it included evaluation for CNS in-
jury by performing complete neurological examination by
pediatric neurologist and in some of them by doing cranial
sonograms, EEG, brain CT and/or MRI hearing test & fun-
dus examination.
2.10. A consent had been taken from parents
The study had been approved from scientiﬁc ethics committee
of Sohag & Assiut University Hospitals.
3. Results
Table 2. Clinical proﬁle of neonates with PPHN.
Clinical parameters No. %
Respiratory distress(RDS) 54 100
Mild 7 12.9
Moderate 30 55.5
Severe 17 31.5
Fast heart rate 46 85.1
Cyanosis 46 85.1
Acidosis 15 27.8
Cardiomegaly 21 38.8
Loud S2 48 88.9
Murmurs (TR) 36 66.7
Hepatomegaly 21 38.9
Hypotension 18 33.3
Hypothermia 5 9.3
Hypoglycemia 11 20.4
Hypocalcaemia 6 11.1
Table 3. Etiological (possible detected risk factors) for
PPHN.
Variable No. %
Fetal factors
Meconium aspiration syndrome (MAS) 19 35.2
Birth asphyxia 10 18.5
Hyaline membrane diseases (HMD) 8 14.8
Infant of diabetic mother(IDM) 7 12.9
Transient tachypnea of newborn 3 5.6
Neonatal pneumonia 6 11.1
Postdate (>40 weeks) 2 3.7
Diaphragmatic Hernia 2 3.7
Lung hypoplesia 1 1.9
Down syndrome 5 9.3
Proven neonatal septicemia 7 12.9
Maternal diseases
Maternal IDM 14 25.9
Maternal hypertension 8 14.8
Maternal anemia 3 5.6
Idiopathic (black lung or clear lung) PPHT 6 14.8
Table 4. Comparison of rate of improvement due to oral
sildenaﬁl and magnesium sulfate.
Variable No. %
Improved 24 44.4
Chronic lung diseases 4 7.4
Neurodevelopment impairment 10 18.5
Missed follow up 4 7.5
Expired 12 22.2
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PPHN represented nearly 3% (541/1801 cases) of total neona-
tal care unit admissions and 11% (54/486 cases) of NICU
admission and it was considered the sixth leading cause of
death in our nursery units in year 2009.
Meconium stained, birth asphyxia, hyaline membrane dis-
eases, neonatal septicemia, post-term birth, large for gesta-
tional age, cesarean section, maternal diabetes mellitus were
associated with an elevated risk for PPHN.The majority of neonates were delivered by CS due to pre-
natal problems.
Numerous publications have reported cesarean section deliv-
ery, including elective cesarean delivery, to be associated with a
high incidence of respiratory distress syndrome and PPHN.
Cesarean section itself might cause PPHN or might be
attributed to underlying fetal conditions that triggered the
intervention and ultimately results in PPHN.
Home delivery carries also a risk for PPHN in those neo-
nates and 90% of neonates proved to have septicemia with
PPHN were home delivered.
Home delivery in our locality is usually performed by non
expert personnel in unclean, unhygienic conditions and usually
associated with high incidence of neonatal infections which
may lead to occurrence of pulmonary hypertension.
Sildenaﬁl citrate promotes selective smooth muscle relaxa-
tion in lung vasculature possibly by inhibiting phosphodiester-
ase type 5 (PDE5). This results in subsequent reduction of blood
pressure in pulmonary arteries and increase in cardiac output.
Oral sildenaﬁl was administered easily and was tolerated
and improved oxygenation index in infants with severe PPHN.
So it may be a useful adjuvant therapy for term infants with
pulmonary hypertension in centers lacking inhaled nitric oxide
and extracorporeal membrane oxygenation.
Intravenous magnesium sulfate (MgS04) has been used
extensively in developing countries for the treatment of PPHN.
It is cheap and easily available, and has a potential neuro-
protective effect. Its main disadvantage is that it can cause sys-
temic hypotension.
The mortality & morbidity rates in our neonates were high-
er than those reported in some previous studies and may be
attributed to late presentation, delayed diagnosis and unavail-
ability of other highly effective therapeutic modalities like in-
haled nitric oxide, extracorporeal membrane oxygenation
(ECMO) and more recently vasodilators agents like tolazoline.
5. Conclusion
Meconium stained, birth asphyxia, hyaline membrane diseases,
neonatal septicemia, post-term birth being large for gestational
age, cesarean section, maternal overweight and diabetes melli-
tus were associated with an elevated risk for PPHN.
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